
Psoriasis vulgaris - Pipeline Insight, 2024
Description
Psoriasis vulgaris - Pipeline Insight, 2024
DelveInsight’s, “Psoriasis vulgaris - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in Psoriasis vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Psoriasis vulgaris: Overview
Psoriasis vulgaris is a chronic skin disorder characterized by the rapid turnover of the epidermis, resulting in the accumulation of thick scale over sites of frequent trauma and irritation. Psoriasis vulgaris is commonly known as chronic plaque psoriasis or plaque psoriasis, characterized by raised, red skin plaques with silvery scales. It is the most common form of psoriasis, affecting between 80-90% of people with psoriasis. Psoriasis is a clinically heterogeneous lifelong skin disease that presents in multiple forms such as plaque, flexural, guttate, pustular, or erythrodermic. The classic skin lesions of psoriasis vulgaris can be described as sharply demarcated, scaly, erythematous plaques often found on the extensor surfaces. Psoriasis is not curable, but it is treatable, and people who think they have psoriasis vulgaris should seek medical attention to confirm the diagnosis and begin treatment as soon as possible.
The pathophysiology of psoriasis is characterized by excessive epidermal growth and altered keratinocyte differentiation. The underlying pathogenesis is multifactorial and complex with genetic, immunologic, and environmental contributions. Certain environmental triggers are thought to disrupt the homeostasis of the skin immune system in genetically predisposed individuals. Medications implicated in the induction and exacerbation of psoriasis include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), antimalarials, lithium, and nonsteroidal anti-inflammatory drugs.
Psoriasis vulgaris is diagnosed primarily through a physical examination of the skin, scalp, and nails for signs of the condition. The doctor may also ask questions about the patient's health, medical and family history, recent illnesses, and severe stress. In some cases, a small skin sample may be taken for examination under a microscope to rule out other skin conditions that look like psoriasis and to determine the type of psoriasis. A skin biopsy is seldom required for diagnosis.
""Psoriasis vulgaris - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis vulgaris pipeline landscape is provided which includes the disease overview and Psoriasis vulgaris treatment guidelines. The assessment part of the report embraces, in depth Psoriasis vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis vulgaris.
This segment of the Psoriasis vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Psoriasis vulgaris Emerging Drugs
- BAT2306: Bio-Thera Solutions
- SGX302: Soligenix
- CAN10: Cantargia AB
- XmAb564: Xencor
Further product details are provided in the report……..
Psoriasis vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Psoriasis vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Psoriasis vulgaris
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Psoriasis vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Psoriasis vulgaris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis vulgaris drugs.
Psoriasis vulgaris Report Insights
- Psoriasis vulgaris Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Psoriasis vulgaris drugs?
- How many Psoriasis vulgaris drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis vulgaris?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis vulgaris therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Psoriasis vulgaris and their status?
- What are the key designations that have been granted to the emerging drugs?
- Xencor
- Ono Pharmaceutical Co. Ltd
- Boehringer Ingelheim
- GC Cell Corporation
- Soligenix
- Cantargia AB
- Huabo Biopharm
- Huaota Biopharmaceuticals
- Bio-Thera Solutions
- Hangzhou Highlightll Pharmaceutical
- Sanofi
- Meiji Pharma
- XmAb564
- BAT-2306
- ONO-4685
- BI 765250
- CT303
- SGX302
- CAN10
- HB0017
- HOT-3010
- TLL018
- SAR441566
- ME3183
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Psoriasis vulgaris: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Psoriasis vulgaris – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- BAT2306: Bio-Thera Solutions
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SGX302: Soligenix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CAN10: Cantargia AB
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Psoriasis vulgaris Key Companies
- Psoriasis vulgaris Key Products
- Psoriasis vulgaris- Unmet Needs
- Psoriasis vulgaris- Market Drivers and Barriers
- Psoriasis vulgaris- Future Perspectives and Conclusion
- Psoriasis vulgaris Analyst Views
- Psoriasis vulgaris Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.